Verification evidence is still being completed.
PDF / print export
Nykode Therapeutics
Oslo, Norway
- Verified lead
- Michael Engsig
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- DNA Vaccines
- Review cycle
- May 2026
- Full address
- Oslo Science Park, Gaustadalléen 21, 0349 Oslo, Norway
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Nykode management page confirming Michael Engsig as CEO.
- Editorial note
- Nykode returns as a strong verified Nordic profile through its live management page and April 2025 company announcement confirming Michael Engsig continues as CEO.
DNA Vaccines
Clinical Phase II ops
Nykode returns as a strong verified Nordic profile through its live management page and April 2025 company announcement confirming Michael Engsig continues as CEO.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated05 Jun 2026, 01:06
Company profile · Oslo, Norway
Nykode Therapeutics
DNA Vaccines · Drug Development
Verified 14 Mar 2026 · 3 sources
VaccineClinical
Nykode returns as a strong verified Nordic profile through its live management page and April 2025 company announcement confirming Michael Engsig continues as CEO.
Contact & location
- Website
- nykode.com
- Company page
- Lead
- Michael Engsig (verified ↗)
- Compliance
- Not yet on record
- Last reviewed
- 14 Mar 2026 (3mo ago)
- Scale
- Drug Development
- Capabilities
- Vaccibody Platform · Targeted Antigen Design · Cancer Immunotherapy
- Founded
- 2007
- Headcount
- 51-200
Clinical profileSTATUS: VERIFIED MARCH 2026
Michael Engsig
Chief Executive Officer
Full addressOslo Science Park, Gaustadalléen 21, 0349 Oslo, Norway
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official Nykode contact page naming the Oslo Science Park headquarters at Gaustadalléen 21.
Open sourceDrug Development
Oslo, Norway. DNA Vaccines. Review completed on 14 Mar 2026.
Statens legemiddelverk
Clinical Phase II ops
DNA Vaccines
Nykode returns as a strong verified Nordic profile through its live management page and April 2025 company announcement confirming Michael Engsig continues as CEO.
Editorial note
Nykode returns as a strong verified Nordic profile through its live management page and April 2025 company announcement confirming Michael Engsig continues as CEO.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Vaccibody Platform
Targeted Antigen Design
Cancer Immunotherapy
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Molecular Design Cluster
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
14 Mar 2026: Executive identity confirmed via official management disclosure.
14 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Nykode Therapeutics located?
- Nykode Therapeutics operates from Oslo Science Park, Gaustadalléen 21, 0349 Oslo, Norway, Oslo, Norway.
- Who runs Nykode Therapeutics?
- Nykode Therapeutics is led by Michael Engsig, Chief Executive Officer. Verified 14 Mar 2026.
- What does Nykode Therapeutics do?
- Nykode returns as a strong verified Nordic profile through its live management page and April 2025 company announcement confirming Michael Engsig continues as CEO. Core capabilities: Vaccibody Platform, Targeted Antigen Design, Cancer Immunotherapy.
Editorial context
Related technical briefs
Briefs that name Oslo as a covered market or city.